Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Vascular Disorders
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Vascular Disorders
    Combining Calcium Scoring, SPECT Gives More Accurate Read on Patients' Heart Risk - (DGNews)
    Differences in atherosclerosis according to area level socioeconomic deprivation: cross sectional, population based study - (BMJ)
    TopAbstracts in Vascular Disorders 10/29/2009 - (DGNews)
    Radial Approach to PCI Associated With Less Bleeding Relative to the Femoral Approach: Presented at CCC - (DGDispatch)
    Perioperative Pattern of Use of Beta Blockers Affects Mortality: Presented at ASA - (DGDispatch)

    News archive

     Recent webcasts/CME - Vascular Disorders
      Arteriovenous Malformations Dural Arteriovenous Shunts
      Physiologic Basis of Hyperglycemia in Macro- and Microvascular Disease
      Varicose Veins: Causes, Symptoms, Diagnosis, and Treatment of Chronic Venous Insufficiency
      Varicose Veins, the Orphan and the Clinician Radiologist
      Aortic Stenosis: Non-Surgical Replacement of the Stenotic Aortic Valve

      Webcasts/CME archive

       Recent cases - Vascular Disorders
        A Simple and Rapid Vascular Anastomosis for Emergency Surgery: A Technical Case Report
        Ascending Aortic Aneurysm in a Patient with Bicuspid Aortic Valve, Positive History of Systemic Autoimmune Diseases and Common Genetic Factors: A Case Report
        Internal Jugular Vein Vascular Malformation Presenting as Mass at Root of Neck: A Case Report
        Leiomyosarcoma of the Inferior Vena Cava: Radical Surgery and Vascular Reconstruction
        Malignant Hypertension and Acute Aortic Dissection Associated with Caffeine-Based Ephedra-Free Dietary Supplements: A Case Report

        Cases archive
          




        my personal edition > vascular disorders > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        New Crestor(R) (rosuvastatin calcium) Indication Approved in U.S. to Slow Progression of Atherosclerosis in Patients With High Cholesterol

          WILMINGTON, DE -- November 15, 2007 -- The U.S. Food and Drug Administration (FDA) has approved Crestor(R) (rosuvastatin calcium) as an adjunct to diet to slow the progression of atherosclerosis in patients with elevated cholesterol.

          The submission package to the FDA was based largely on the results of a pivotal study called METEOR (Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin).

          The METEOR study measured the effects of Crestor on plaque build-up in the arteries using carotid intima-media thickness (CIMT) and demonstrated a slowing of progression of atherosclerosis in people with early signs of the disease, elevated low-density lipoprotein cholesterol (LDL-C), and low cardiovascular risk, taking Crestor 40 mg.

          The METEOR study is part of the GALAXY Program, a large, comprehensive, long-term and evolving global research initiative designed to address important unanswered questions in statin research and to investigate the impact of Crestor on cardiovascular risk reduction and patient outcomes. To date, the GALAXY Program has recruited more than 69,000 subjects in more than 55 countries around the world.

          The new Crestor label conforms to the FDA's revised, easy-to-read format designed to draw physicians' attention to the most important pieces of drug information in an effort to manage the risks of medication use and reduce medical errors.

          Atherosclerosis is the progressive buildup of plaque -- the fatty deposits and other cells -- in the inner walls of the arteries. The condition is a consequence of elevated cholesterol and for many it's a silent disease, with no visible signs or symptoms. The disease can begin in early adulthood and continues to progress for the rest of a person's life. Despite the serious nature of atherosclerosis, many people do not understand how it develops and progresses.

          Crestor is indicated as adjunctive therapy to diet to reduce elevated Total-C, LDL-C, apolipoprotein B, non-high-density lipoprotein cholesterol (HDL-C), and triglycerides and to increase HDL-C in adult patients with primary hyperlipidemia or mixed dyslipidemia. It is also indicated as an adjunct to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower Total-C and LDL-C to target levels. The drug has not been determined to prevent heart disease, heart attacks, or strokes.

          For patients with hypercholesterolemia and mixed dyslipidemia, the usual recommended starting dose of Crestor is 10 mg. The 40-mg dose of Crestor is reserved only for those patients who have not achieved their LDL-C goal utilizing the 20-mg dose of Crestor once daily.

          When initiating statin therapy or switching from another statin therapy, the appropriate Crestor starting dose should first be utilized, and only then titrated according to the patient's individualized goal of therapy.


          SOURCE: AstraZeneca




        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2009 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send